Nurix Therapeutics, a Celgene-backed cancer treatment developer based on UC Berkeley and San Francisco research, priced shares above its range to raise $209m.
Nurix Therapeutics, a US-based oncology therapy developer based on research at University of California (UC), Berkeley and UC San Francisco, priced its shares at $19 on Thursday and raised $209m when it went public on Friday.
The company issued 11 million shares on the Nasdaq Global Market and is trading under the ticker symbol NRIX. Nurix had initially planned to sell 8.8 million shares priced at $16 to $18.
Founded in 2009 as Kura Therapeutics, Nurix is…
